.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin caused boosted progression-free and general survival, resulting in FDA commendation and a brand-new procedure possibility for patients.